A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway

Oncogene

Volumn 26, Issue 26, 2007, Pages 3777-3788

  Carie, A E ^a,b   Sebti, S M ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

2 adrenergic receptor; cAMP; Cancer therapy; Erk1 2; Pirbuterol; Raf 1

Indexed keywords

ANTIPORTER; ARA 211; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; EXCHANGE PROTEIN ACTIVATED BY CYCLIC AMP; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PIRBUTEROL; RAF PROTEIN; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER INHIBITION; CANCER REGRESSION; CONTROLLED STUDY; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; KIDNEY TUMOR; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADRENERGIC BETA-AGONISTS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC AMP; ETHANOLAMINES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MAP KINASE KINASE 1; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 34249931195     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210172     Document Type: Article

References (52)

1. Alvarez JV, Frank DA. (2004). Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis. Cancer Biol Ther 3: 1045-1050.
2. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. (2003). Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63: 1270-1279.
3. Bos JL. (1989). Ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689.
4. Carman CV, Benovic JL. (1998). G-protein-coupled receptors: turn-ons and turn-offs. Curr Opin Neurobiol 8: 335-344.
5. Cox ME, Deeble PM, Bissonette EA, Parsons SJ. (2000). Activated 3′,5′-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line. J Biol Chem 275: 13812-13818.
6. Dhillon AS, Kolch W. (2002). Untying the regulation of the Raf-1 kinase. Arch Biochem Biophys 404: 3-9.
7. Di Marco E, Pierce JH, Fleming TP, Kraus MH, Molloy CJ, Aaronson SA et al. (1989). Autocrine interaction between TGF alpha and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 4: 831-838.
8. Dumaz N, Marais R. (2005). Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. FEBS J 272: 3491-3504.
9. English JM, Cobb MH. (2002). Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 23: 40-45.
10. Enserink JM, Christensen AE, de Rooij J, van Triest M, Schwede F, Genieser HG et al. (2002). A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK. Nat Cell Biol 4: 901-906.
11. Erhardt P, Troppmair J, Rapp UR, Cooper GM. (1995). Differential regulation of Raf-1 and B-Raf and Ras-dependent activation of mitogen-activated protein kinase by cyclic AMP in PC12 cells. Mol Cell Biol 15: 5524-5530.
12. Fleming TP, Matsui T, Aaronson SA. (1992). Platelet-derived growth factor (PDGF) receptor activation in cell transformation and human malignancy. Exp Gerontol 27: 523-532.
13. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. (2004). PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193-204.
14. Graells J, Vinyals A, Figueras A, Llorens A, Moreno A, Marcoval J et al. (2004). Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol 123: 1151-1161.
15. Grassi V, Daniotti S, Schiassi M, Dottorini M, Tantucci C. (1986). Oral beta 2-selective adrenergic bronchodilators. Int J Clin Pharmacol Res 6: 93-103.
16. Graves LM, Bornfeldt KE, Raines EW, Potts BC, Macdonald SG, Ross R et al. (1993). Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci USA 90: 10300-10304.
17. Hafner S, Adler HS, Mischak H, Janosch P, Heidecker G, Wolfman A et al. (1994). Mechanism of inhibition of Raf-1 by protein kinase A. Mol Cell Biol 14: 6696-6703.
18. Hagemann C, Blank JL. (2001). The ups and downs of MEK kinase interactions. Cell Signal 13: 863-875.
19. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70.
20. Hao D, Rowinsky EK. (2002). Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and Ras inhibitors. Cancer Invest 20: 387-404.
21. Jiang Z, Wu CL, Woda BA, Iczkowski KA, Chu PG, Tretiakova MS et al. (2004). Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. Histopathology 45: 218-225.
22. Jin W, Wu L, Liang K, Liu B, Lu Y, Fan Z. (2003). Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer 89: 185-191.
23. Johnson GL, Lapadat R. (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912.
24. Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J et al. (2005). Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 11: 6414-6421.
25. Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM. (1997). Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 15: 1283-1288.
26. Maudsley S, Pierce KL, Zamah AM, Miller WE, Ahn S, Daaka Y et al. (2000). The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem 275: 9572-9580.
27. Moore PF, Constantine JW, Barth WE. (1978). Pirbuterol, a selective beta2 adrenergic bronchodilator. J Pharmacol Exp Ther 207: 410-418.
28. Redell MS, Tweardy DJ. (2005). Targeting transcription factors for cancer therapy. Curr Pharm Des 11: 2873-2887.
29. Schmitt JM, Stork PJ. (2001). Cyclic AMP-mediated inhibition of cell growth requires the small G protein Rap1. Mol Cell Biol 21: 3671-3683.
30. Schmitt JM, Stork PJ. (2002). PKA phosphorylation of Src mediates cAMP's inhibition of cell growth via Rap1. Mol Cell 9: 85-94.
31. Sebolt-Leopold JS. (2000). Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19: 6594-6599.
32. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC et al. (1999). Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5: 810-816.
33. Sebti SM, Tkalcevic GT, Jani JP. (1991). Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. Cancer Commun 3: 141-147.
34. Sevetson BR, Kong X, Lawrence Jr JC. (1993). Increasing cAMP attenuates activation of mitogen-activated protein kinase. Proc Natl Acad Sci USA 90: 10305-10309.
35. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
36. Slotkin TA, Seidler FJ. (2000). Antimitotic and cytotoxic effects of theophylline in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat 64: 259-267.
37. Slotkin TA, Zhang J, Dancel R, Garcia SJ, Willis C, Seidler FJ. (2000). Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat 60: 153-166.
38. Steen SN, Ziment I, Thomas JS. (1974). Pyrbuterol: a new bronchodilator. Phase I-single dose study. Curr Ther Res Clin Exp 16: 1077-1081.
39. Steinberg SF. (2000). The cellular actions of beta-adrenergic receptor agonists: looking beyond cAMP. Circ Res 87: 1079-1082.
40. Stork PJ, Schmitt JM. (2002). Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12: 258-266.
41. Strobl JS, Wonderlin WF, Flynn DC. (1995). Mitogenic signal transduction in human breast cancer cells. Gen Pharmacol 26: 1643-1649.
42. Sun J, Ohkanda J, Coppola D, Yin H, Kothare M, Busciglio B et al. (2003). Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice. Cancer Res 63: 8922-8929.
43. Sun J, Wang DA, Jain RK, Carie A, Paquette S, Ennis E et al. (2005). Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene 24: 4701-4709.
44. Tortora G, Ciardiello F. (2002). Protein kinase A as target for novel integrated strategies of cancer therapy. Ann NY Acad Sci 968: 139-147.
45. Troadec JD, Marien M, Mourlevat S, Debeir T, Ruberg M, Colpaert F et al. (2002). Activation of the mitogen-activated protein kinase (ERK(1/2)) signaling pathway by cyclic AMP potentiates the neuroprotective effect of the neurotransmitter noradrenaline on dopaminergic neurons. Mol Pharmacol 62: 1043-1052.
46. Veber N, Prevost G, Planchon P, Starzec A. (1994). Evidence for a growth effect of epidermal growth factor on MDA-MB-231 breast cancer cells. Eur J Cancer 30A: 1352-1359.
47. Vossler MR, Yao H, York RD, Pan MG, Rim CS, Stork PJ. (1997). cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell 89: 73-82.
48. Watanabe M, Nobuta A, Tanaka J, Asaka M. (1996). An effect of K-ras gene mutation on epidermal growth factor receptor signal transduction in PANC-1 pancreatic carcinoma cells. Int J Cancer 67: 264-268.
49. Weinstein-Oppenheimer CR, Blalock WL, Steelman LS, Chang F, McCubrey JA. (2000). The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. Pharmacol Ther 88: 229-279.
50. Weldon CB, Scandurro AB, Rolfe KW, Clayton JL, Elliott S, Butler NN. (2002). Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery 132: 293-301.
51. Wu J, Dent P, Jelinek T, Wolfman A, Weber MJ, Sturgill TW. (1993). Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science 262: 1065-1069.
52. Yu M, Sato H, Seiki M, Spiegel S, Thompson EW. (1998). Elevated cyclic AMP suppresses ConA-induced MT1-MMP expression in MDA-MB-231 human breast cancer cells. Clin Exp Metastasis 16: 185-191.